Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (Guangzhou General Hospital of Guangzhou Military Command)
- Development stage
- Unknown
- Lead developer
- General Hospital of Southern Theater Command of the People's Liberation Army
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
h-Guangzhou General Hospital of Guangzhou Military Command-spinal cord injury refers to an investigational autologous cell therapy developed by the Guangzhou General Hospital of Guangzhou Military Command for the treatment of spinal cord injury. The therapy consists of mesenchymal stem cells (MSCs) derived from the patient's own bone marrow, which are expanded in culture and then administered through a combination of intravenous and intrathecal routes. This dual-route approach is intended to maximize the delivery of cells to the site of injury. The therapeutic effects are believed to be mediated by the cells' paracrine activity, immunomodulatory properties, and potential for neural differentiation, aimed at reducing inflammation and promoting axonal regeneration in patients with traumatic thoracic or lumbar spinal cord injuries.
- Other names
- autologous bone marrow-derived mesenchymal stem cellsBM-MSCs
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (Guangzhou General Hospital of Guangzhou Military Command).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (Guangzhou General Hospital of Guangzhou Military Command).